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Abstract

SPHINGOSINE KINASE 1 INHIBITOR, A NOVEL INDUCER OF AUTOPHAGY
By Daniel Meza B.A.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Sarah Spiegel, Ph.D.,
Professor and Chair, Department of Biochemistry and Molecular Biology

Autophagy is the process of “cell self-eating” which has been implicated both in
cell survival and cell death. Sphingosine kinase 1 (SphK1) regulates the intracellular
balance between ceramide and sphingosine, bioactive lipids associated with cell death, and
sphingosine-1-phosphate (S1P), whose actions are associated with survival and
proliferation. Previous studies have implicated upregulation of SphK1 in the induction of
autophagy.

In this study, SK1-I, a SphK1 specific competitive inhibitor, induced

autophagy in a concentration and time dependent manner in HCT116 colorectal carcinoma
cells.

This autophagic response was observed to be more intense in wild type p53

xii

expressing HCT116 cells than in p53 null cells and ultimately led to non-apoptotic death in
wild type and apoptotic death in p53 null cells. In agreement, cell death in wild type cells
was not accompanied by cleavage of polyADP ribose polymerase, a hallmark of apoptosis.
Knockdown of Beclin 1 demonstrated that it and its binding partners do not have a
significant role in the induction of autophagy in response to SK1-I treatment. Similarly,
mTORC1 signaling was not observed.

In contrast, SK1-I markedly decreased Akt

phosphorylation. However, this might not be the sole factor important for SK1-I induced
autophagy, as pharmacological inhibition of Akt only led to a comparatively weak
autophagic response. Indeed, phosphorylation of the endoplasmic reticulum (ER) stress
marker eIF2 α, was greatly reduced, suggesting that an ER mediated mechanism also
contributes to SK1-I induced autophagy. Thus, SK1-I induced autophagy was likely
triggered by ER stress signaling and led to non-apoptotic cell death in the more highly
autophagic wild type 53 expressing cells. These results suggest that an isotype specific
SphK1 inhibitor might be a useful adjunct for the treatment of cancer or other diseases in
which

enhancement

of

cytotoxicity

xii

or

autophagy

is

desirable.

Introduction

Autophagy
Autophagy is catabolism of a cell's own contents through lysosomal degradation.
Four broad categories of autophagy have been described: microautophagy, crinophagy,
chaperone mediated autophagy and macroautophagy1, 2. These forms differ in their
identification and trafficking of substrates to the lysosome.

In microautophagy, the

lysosomal membrane directly engulfs its substrate3. In crinophagy secretory vesicles fuse
with the lysosome4.

In chaperone mediated autophagy, cytosolic chaperones (Hsc70

complex) deliver proteins directly to the lysosome based on a pentapeptide consensus
motif within the substrate5. Macroautophagy, the form of autophagy investigated in this
study (henceforth referred to as autophagy), involves the formation of a distinctive double
membraned vesicle, the autophagosome, which first envelops a portion of intracellular
contents including cytosol and organelles6 , matures, then fuses with the lysosome.

Roles of Macroautophagy
Mammalian macroautophagy most commonly occurs in response to nutrient
starvation and acts to support cell survival. Amino acid starvation (differing based upon
the tissue and amino acid)7 and growth factor withdrawal 8 have been shown to induce an
14

autophagic survival response.

At the organismal level, nutrient starvation-induced

autophagy is proposed to be hormonally controlled, as, for example, in the liver, where
suppression of autophagy by insulin and induction of autophagy by glucagon is observed9 .
It is also well known that basal autophagy plays an important housekeeping role as
the primary mechanism for degradation of long-lived proteins7 . Accordingly, it has been
proposed that induction of autophagy could be a treatment for neurological disorders such
as Huntington's, Alzheimer's, and Parkinson's diseases by degrading abnormal protein
accumulations10,

11

.

Autophagy has also been theorized to support immune major

histocompatibility complex 1 and 2 formation through the engulfment and degradation of
intracellular pathogens12 .
Observations of autophagy induction by nutrient starvation, and the housekeeping
role of autophagy in degrading long-lived proteins have led to the characterization of
autophagy as a process of nonspecific mass degradation. Recently, however, it has been
noted that mammalian autophagy plays a role in regulating intracellular homeostasis,
including that of reactive oxygen species (ROS)13-16 and attenuating the effects of
pathogenic intracellular bacteria and viruses17 . Proteomic analysis of autophagic cells
indicates that degradation of cell contents via autophagy appears to be regulated at the
protein complex/organelle level in a manner specific to the conditions triggering the
autophagic response18 .
In keeping with this emerging homeostatic, organelle-focused understanding of
autophagy, changes in endoplasmic reticulum homeostasis, related to both calcium release
and protein misfolding, strongly influence autophagic response19 . Furthermore, several
15

autophagy-related proteins appear specifically localized to the ER18,

20, 21

.

These

characteristics of autophagy induction and localization will be considered in the following
sections and may lend further insight into the mechanisms regulating autophagy.
In opposition to the homeostatic role proposed for autophagy, numerous recent
studies have used inhibition of autophagy by the phosphatidylinositol 3-kinase (PI3Kinase)
inhibitor 3-methyladenine (3MA) and downregulation of expression of autophagy related
proteins to demonstrate that inhibition of autophagy prevents cell death under conditions
which normally elicit non-apoptotic death22 . These observations have been used to assert
that autophagy is capable of inducing cell death in a non-apoptotic fashion.
The dichotomous role of autophagy in cell survival has become an important issue
in understanding tumorigenesis23 .

Although autophagy appears to suppress tumor

development in animals, its pro-survival role during nutrient scarcity may be essential for
the survival of quickly proliferating tumor cells. Evidence that autophagy related genes are
frequently deleted in cancer, and that cancer cells seem deficient in autophagy, suggest that
autophagy is anti-tumorigenic. Several oncogenes, such as Bcl-2 and Akt, have been
shown to play a central role in attenuating autophagy, while tumor suppressor genes, such
as DAPK and Beclin 1, are pro-autophagic. In addition, chemotherapeutic agents, such as
rapamycin have been shown to function via an autophagic killing mechanism24 . Even so,
the possibility exists that the autophagic response in these conditions is engaged to
promote survival rather than death.

16

Autophagosome Formation and Maturation
The structural, enzymatic, and mechanistic elements of autophagy induction are
beginning to be understood.

These elements have typically been characterized as

contributing to one of two phases of the autophagic process: autophagic vesicle formation
or autophagosome maturation.

Autophagosome Maturation
While Atg5, LC3, and perhaps Beclin 1 complexes are now considered essential in
regulating initial autophagic vesicle formation25-27, enclosed vesicles undergo maturational
changes leading to lysosomal fusion under the regulation of another, possibly distinct, set
of factors. During maturation, autophagosomes acquire lysosomal membrane proteins,
experience an increase in cholesterol content in their outer membrane and become more
acidic28-31. It has been proposed that in mammals this maturation process occurs through
autophagosome fusion with early and late endosomal vesicles31. It has been observed that
hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) protein, known to be
involved in receptor regulation by endocytosis32, localizes to autophagosomes and its
deletion inhibits autophagolysosme formation and multivesicular endosome formation33.
Similarly, in mouse, a dominant negative form of suppressor of potassium transport growth
defect 1 (SKD1, an ATPase) inhibits fusion of autophagosomes with endosomes causing a
deficit in bulk protein degradation34. Fusion of autophagosomes with lysosomes in yeast is
inhibited by knockdown of Rab7 small GTPase

35, 36

and Vti1p SNARE protein37.

Lysosome Associated Membrane Protein 1 and 2 (LAMP1 and 2), which constitute the
17

majority of lysosomal membrane proteins, are also thought to be involved in
autophagosome fusion. However, its knockout increases autophagosome and cholesterol
accumulation without attenuating long-lived protein degradation29.

Throughout this

process, microtubules are thought to play a role in the production of autophagosomes. It
has been noted that microtubules carry autophagosomes toward the microtubule-organizing
center38.

Furthermore, traffic of autophagosomes requires cytoplasmic, microtubule-

associated, histone deacetylase 639.
In mammalian cells, autophagic vesicle formation has commonly been associated
with the activity and localization of three autophagy related proteins (Atg): Atg5, LC3
(Atg8), and Beclin 1(Atg6).

The precise roles of these proteins in forming the

autophagosome, however, are not yet well understood.

Atg5
Atg5 is a member of the Atg family first identified in yeast. Atg5 has been shown
to be necessary for survival in mice40 and has recently been implicated in both autophagy
and apoptosis (after calpain cleavage)41. Atg5 protein capable of conjugation to another
Atg protein, Atg12, is necessary for elongation of the isolation membrane (initiation of
autophagosome formation) in mammals25 (Fig. 1).
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Figure 1: Atg5 and LC3II contribute to early formation of the autophagosome.42
Beclin1 in complex with type 3 phosphotidyl inositol 3 phosphate kinase produces
phosphatidyl inositol 3 phosphate (PtdINs3P), considered necessary for autophagosome
formation and implicated in the localization of the isolation membrane. Atg12-Atg15
(autophagy protein) are shown to be necessary for autophagosome formation and act as E3
type ligases for lipidation of LC3I to LC3II. LC3II is necessary for elongation and
completion of the autophagic vesicle. Atg5-Atg12 leaves the isolation membrane when it
closes to form the autophagosome. LC3II is completely shed and degraded from the
autophagosome after fusion with the lysosome.
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In this ATP dependent process, Atg12 ubiquitin-like protein is covalently conjugated to
Atg5 via the E1-ligase activity of Atg7 and the E2 like activity of Atg1043-47. The Atg5Atg12 complex has been shown to localize to autophagosome precursors (the isolation
membrane) and to dissociate from the autophagosome upon closure of the autophagic
vesicle (isolation membrane)48.

Atg5 is in complex with Atg16L and Atg12, yet

knockdown of each of these proteins inhibits autophagosome formation at different
stages49. Nonetheless, this complex has been shown to play necessary role in the next step
of this process, LC3 lipidation.

LC3
LC3 is a soluble, microtubule associated protein50 that was observed to associate
with the inner and outer membrane of the elongating autophagosome26. For completion of
the autophagic vesicle, cytosolic LC3I (Atg4 cleaved LC3) must be covalently conjugated
to phosphatidyl-ethanolamine to form LC3II, a ubiquitin-like modification requiring Atg7
and Atg351. In yeast and mouse, the Atg5-Atg12 conjugate functions as an E3-like enzyme
for this lipidation reaction48, 52. In addition, the Atg5-Atg12 dimer binds Atg16L, homooligomerizing to form 800 kilodalton complexes in mammals53, 54. The intracellular site of
LC3 lipidation appears to be determined by the localization of the Atg16L complex.
Ectopic LC3 lipidation can be induced by changes in Atg16L localization49. In humans,
Atg16L1, a single common coding variant of this protein, predisposes individuals to
development of Crohn's disease (an inflammatory illness of the digestive tract) and shows

20

impairment in the capture of Salmonella within autophagosomes55. This LC3 lipidation
system is also implicated in lipid droplet formation56.
LC3II, although targeted to the Atg5-Atg12 associated autophagosomal precursors,
is retained in the outer leaflet until autophagosome maturation36 and is thought to be
degraded on the inner leaflet only with lysosomal fusion57. As such, it has proven to be an
important marker for pre-lysosomal autophagosomes.

Beclin (Atg6)
Beclin1 is a well characterized tumor suppressor gene27, 58 homoallelically deleted
in many human tumors. In breast cancer, Beclin1 haploinsufficiency causes defective
autophagy, but restoration of Beclin1 induces autophagy and inhibits tumorigenicity27.
Beclin 1's autophagic role is thought to be as binding partner of Vps34 type 3 PI3Kinase59.
The association of Beclin 1 with Vps34 has been shown to induce the production of lipid
scaffolding molecule phosphatidylinositol 3-phosphate (PI3P) which is considered
necessary for autophagosome nucleation59. In yeast, Beclin1 orthologue-produced PI3P
has been suggested to recruit proteins required for autophagosome formation based on
association with FYVE or PX motifs60,

61

. In rat cerebral cortex, Beclin 1 appears to

localize to membrane rafts and dissociates from them during traumatic brain injury induced
autophagic events62. In HCT116 colon cancer cells, Beclin 1 localizes to mitochondria and
nucleus63 other eukaryotic cells, Beclin 1 has been observed to localize to the trans-Golgi
and ER that serve as foci of PI3P formation59. Serine threonine kinase p150 may mediate
this membrane association of the Beclin 1 PI3kinase complex64.
21

A number of Beclin1 binding proteins regulate the induction of autophagy through
their influence on the association of Beclin1 with Vps34. This association is positively
regulated by UV radiation resistance-associated gene tumor suppressor (UVRAG) and the
activating molecule in Beclin 1-regulated autophagy protein 1 (Ambra1)65, 66 resulting in
increased induction of autophagy. In HCT116 cells, a heterozygous mutation inhibits
UVRAG activity and restoration of UVRAG increases autophagy and attenuates cell
proliferation65.
Binding of Bcl-2 to Beclin1's Bcl-2 homology domain (BH3 domain) is a second
and critical mechanism by which Beclin1's induction of autophagy is regulated. Binding
of Bcl-2 to Beclin1 impedes the association of Beclin1 with Vps34. Furthermore, Bcl-2binding-defective Beclin 1 mutants induce autophagy leading to caspase-independent
autophagic cell death67. Specific Bcl-2 localization to the ER blocks autophagosome
accumulation in response to Xestospongin B (an inositol 1,4,5-triphosphate receptor
(IP3R) inhibitor), vitamin D analogue EB1089 (inducer of ER calcium release), ATP
depletion, and starvation20, 59, 68, whereas localization to other intracellular compartments
does not.

As such, Bcl-2 has emerged as the principal negative regulator of Beclin1

activity.
Bcl -2 binding to Beclin1 is itself mediated by two mechanisms. The first is
competitive inhibition of Bcl-2 Beclin 1 binding by other BH3 proteins.

This was

demonstrated using Bad and BH3 mimetic compound ABT737. While BH3 binding of
Bcl-2 is capable of inducing autophagy of mitochondria, it is not capable of inducing
autophagy in the ER (notwithstanding its ability to disrupt ER Beclin1-Bcl-2 complexes)20
22

. The second mechanism by which Bcl-2 binding appears to be regulated is through
phosphorylation of Bcl-2.

In response to tamoxifen and starvation, Pattingre et al.

observed increased accumulation of autophagic vesicles. This was explained by induction
of Bcl-2 phosphorylation which caused its dissociation from Beclin 1. Ceramide activation
of cJun N-terminal kinase (JNK) was required to phosphorylate Bcl-2 and to stimulate
autophagy69.
Beclin1's presence in the ER also allows it to interact with the IP3R (an ER
membrane calcium channel) which, when in complex with Beclin1, appears to inhibit the
induction of autophagy. This effect is increased by overexpression and binding of Bcl-221 .
Furthermore, autophagy induced by pharmacological inhibition of receptor activity or
IP3R downregulation due to nutrient starvation, is both Calcium and mTORC1
independent21 .
Interestingly, one case of Beclin 1 independent autophagy has been observed.
Scarlatti et al. reported that Resveratrol, a phytoalexin with anti-cancer properties produced
by plants in response to bacterial infection, causes an increase in autophagy in MCF7 cells.
Knock down of Beclin 1 and Vps 34, and inhibition of Vps34 using specific inhibitor 3
methyladenine (3MA), had no effect on autophagic vesicle formation or degradation of
long-lived proteins in Resveratrol treated cells70 .

Signaling Mediators of Autophagy
Potential upstream mediators of autophagosome formation integrate signals
encoding the health of the cell and its environment. Two integrative signaling factors have
23

been shown to significantly correlate with autophagic induction. In many cases, these
factors appear closely intertwined, suggesting that their interactions act as the cellular
circuitry for deciding whether or not to mount the autophagic response. The first is
mammalian target of rapamycin (mTOR).

mTOR
mTOR has been characterized as forming two complexes: mTORC1 and
mTORC271,

72

.

mTORC1 is composed of raptor (scaffolding protein), PRAS40 and

mLST873. Activity of the complex is directly inhibited by treatment with rapamycin which
binds raptor and disrupts its interaction with mTOR74.
mTORC1 is thought to integrate a number of nutrient and growth factor pathways
including those containing Akt75, ERK76, AMP kinases77 and Rsk178. Sancak79 theorized
that in response to signaling events upstream, Rag small GTPase complex binds to Raptor
which stimulates mTOR by changing localization of mTORC1 to perinuclear
endomembrane structures where mTORC1 can be activated by Rheb small GTPase. The
specific mechanism of activation is unknown. The direct substrates of mTORC1 are
p70S6Kinase, 4E-BP180,81, and Pras 4082. P70S6 kinase, in turn, is the major protein
kinase responsible for mTOR ser-2448 phosphorylation83 .
Direct mTORC1 inhibition by rapamycin has been shown to induce autophagy.
mTORC1 inhibition is necessary for nutrient starvation induced autophagy84-86. Elevated
mTORC1 activity results in cells with impaired ability to initiate autophagy in response to
nutrient starvation85. Reduced mTORC1 activity has been observed in autophagic cells as
24

a result of ER stress associated with calcium activated AMPK signaling68, and JNK
upregulation87, elevated SphK1 expression88, elevated ceramide levels69, and Safingol a
SphK1 and PKC inhibitor89. Nonetheless, changes in mTORC1 activity have not been
observed in autophagy induced by PKCθ in response to calcium90, or IP3R in response to
reduction in IP3R expression91.
mTORC2 is composed of mTOR, rictor, mSin1, mLST8 and PRR592-95.

In

response to growth factors but not nutrients, mTORC2 phosphorylates Akt on serine 473 95
(this may be a separate population of Akt than that upstream of mTORC1).

In addition,

turn motif phosphorylation involved in folding of Akt and conventional PKC is dependent
on mTORC2 function96. Overall, mTORC2 activity has been primarily associated with
actin cytoskeletal rearrangement involving PKCα and GTPases Rho and Rac which signal
through unknown effectors97, 98. Recently mTORC2 has proven to have direct relevance to
autophagy as well. mTORC2 inhibition induces FoxO3 transcription of BCL2/adenovirus
E1B 19kDa interacting protein 3 (BNIP3)99, a BH3-only protein100 whose upregulation is
necessary and sufficient for induction of autophagy.

Endoplasmic Reticulum
The endoplasmic reticulum also appears to have a central role in regulating
autophagy (Fig 2). In addition to localization of Beclin and its binding partners to the ER,
changes in ER homeostasis mediated by factors regulating the unfolded protein response
and ER calcium balance, also induce autophagy. The ER is a central regulatory apparatus
for protein folding and trafficking, intracellular calcium homeostasis, and synthesis of
25

unsaturated fatty acids, sterols and phospholipids. Disruption of any of these functions
results in ER stress101. Increasingly, the sensors of ER homeostasis have been implicated
in the induction of autophagy. Homeostatic imbalances of the ER are caused in different
ways by a variety of pharmacological agents: thapsigargin disrupts ER calcium
homeostasis, tunicamycin inhibits protein n-glycosylation, Brefeldin A blocks protein
transport to the Golgi, polyglutamine proteins form protein aggregates

102

and long chain

lipid molecules, such as palmitate103, induce decreases in luminal calcium104. In response
to these insults, three membrane proteins act as parallel sensors triggering transcriptional
effects: protein kinase r-like ER kinase (PERK), which phosphorylates eukaryotic
initiation factor 2α (eIF2α) and induces C/EBP homologous protein

(CHOP)

transcription105, inositol-requiring kinase 1 (IREα1), which binds tumor necrosis factor
receptor-associated factor 2 (TRAF-2) inducing splicing of XBP-1 transcription factor and
stimulating JNK activity101, and activating transcription factor 6 (ATF6), which
translocates to the nucleus and induces transcription of ER-specific member of heat shock
protein 70 family Grp78/BiP (Glucose Response Protein 78/Binding Immunoglobulin
Protein)106. Each appears to have differential sensitivity to stress stimuli, PERK being
activated most quickly in response to calcium changes, PERK and IREα1 responding
equally quickly to protein misfolding, and ATF6 responding slowly to protein
misfolding107. It has been theorized that ER chaperone GRP78/BiP mediates this effect
through its binding inhibition of PERK, IREα1 and ATF6. BiP is also required for stressinduced autophagy108.
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Figure 2: ER stress pathways implicated in autophagy109 There are three ER
stress responsive proteins whose activity appears to be affected by ER calcium levels,
accumulation of misfolded proteins, inhibition of transport from the ER etc., disruptions of
ER equilibrium which are known to result in changes in transcription that define ER stress.
They are: protein kinase r-like ER kinase (PERK), activating transcription factor 6 (ATF6),
and inositol-requiring kinase 1 (IRE1). While ATF6 knockdown has not been shown to
affect autophagy in response to ER disequilibrium, knockdown of PERK and IRE1, along
with eIF2alpha and JNK downstream targets, has been shown to inhibit autophagy and are
therefore thought to be necessary for autophagy in response to different forms of ER stress.
Independent of these three proteins are autophagic responses to cytosolic calcium increases
which can be induced by calcium release from the ER and are calcium/calmodulin
dependent kinase kinase-beta (CaMKKBeta), AMP kinase, and mTOR dependent. Direct
inhibition of ER-bound inositol (1,4,5) triphosphate receptor also appears to induce
autophagy.

27

Both PERK and IREα1 have been found necessary for induction of autophagy. In
one case, PERK and eIF2α were required for autophagic response induced by aggregation
of polyglutamine repeat proteins, but IREalph1 and ATF6 were not102. Alternatively
IREα1, TRAF2 and JNK were required for autophagy in response to thapsigargin and
tunicamycin, while PERK and ATF6 were not110.
It has been proposed that increased cytosolic calcium due to ER calcium release is
responsible for autophagy signaling by the ER68. Calcium release from the ER can be
induced by a number of different agents, including vitamin D analogues, thapsigargin
inhibition of ER calcium transporter (SERCA)111, ATP induced opening of IP3R
channels68 , and accumulation of unfolded proteins in the ER lumen112.
One explanation of ER calcium release induced autophagy attributes regulation of
this response to calcium/calmodulin-dependent kinase kinase-beta activation of AMPK
that leads to inhibition of mTORC168.
Another possibility is PKCθ phosphorylation which is required for the ER-stress
induced autophagic response but unnecessary for amino acid starvation induced autophagy.
PKCθ phosphorylation induces autophagy in a calcium dependent manner independent of
mTORC1.

PKCθ phosphorylation is not dependent upon ER sensors PERK, IRE1 or

ATF6, but its autophagic effect is inhibited by knockdown of IRE1 and eIF2α90.
Increases in cytosolic calcium also activate the death associated protein kinases
(DAPK)113 and calpain proteases114, both of which induce autophagosome formation.
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Sphingosine-1- Phosphate (S1P)
S1P is a bioactive lipid signaling molecule containing a sphingoid long chain base
attached to a phosphate group. S1P has been shown to have a remarkable array of roles
within the cell. Once considered only the end metabolite of all sphingolipids, it is now
known to regulate cell growth115,

116

, suppress apoptosis117, contribute to cytoskeletal

rearrangements and cell motility118-120, invasion, angiogenesis and vascular maturation121,
122

, and trafficking of lymphocytes123. It has also been proposed to play an important role

in the regulation of intracellular calcium124, which may contribute to its varied influences.
By contrast, its precursors, ceramide (N-acylsphingosine) and sphingosine are associated
with cell-growth arrest, stress responses, and apoptosis. Thus a regulatory balance has
been theorized between S1P and ceramide125.
Many of the effects of S1P are mediated by five G-protein coupled receptors (S1P15)

for which S1P and dihydroS1P are the high affinity ligands125. The varying effects of

S1P have been ascribed to the differential distribution of these receptors on each cell and
their differential coupling to G proteins. S1P1 couples to Gi126, S1P3-5 to Gi or G12/13 and
S1P2 may couple to Gs, Gq or G12/13127. This engages signaling cascades which involve
small GTPases128, adenylate cyclase127, inhibition of phospholipase C

129

or inhibition of

Akt and ERK1/2 phosphorylation130, 131. In addition, cells are capable of secreting S1P,
which is thought to act in an autocrine/paracrine fashion on these receptors132. Little,
however, is known about S1P's intracellular targets.
S1P is not biosynthesized de novo and can only be formed from sphingosine
produced during turnover of complex sphingolipids by phosphorylation catalyzed by two
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sphingosine kinase isoenzymes, SphK1 and SphK2 (Fig. 3). De novo ceramide synthesis
begins with the rate limiting condensation of L-serine with palmitoyl-CoA at the cytosolic
leaflet of the ER133.

The product, 3-keto-sphinganine, is reduced and N-acylated to

dihydroceramide. A trans 4,5 double bond is inserted into dihydroceramide by desaturase
to form ceramide134. Inhibition of this desaturase produces non-Beclin dependent
autophagy135. Ceramide production can be induced by hypoxia, various pharmacological
agents and tumor necrosis factor α136, 137. Ceramides are shuttled to the Golgi by CERT, a
cytoplasmic

protein

with

a

phosphatidylinositol-4-phosphate

binding

domain138.

Ceramides are then converted into sphingomyelins by sphingomyelin synthase on the
lumenal side of the Golgi, or to glucosylceramides (whose accumulation is associated with
lysosomal storage disorders) on the cytosolic surface of the Golgi139.
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Figure 3: Sphingolipid Synthesis 140 Sphingosine 1 Phosphate (S1P) is the
product of sphingosine (Sph) phosphorylation by sphingosine kinases (SK) which occurs at
the plasma membrane and may also occur at other intracellular locations. Sph is the result
of removal of a fatty acid chain from ceramide (cer). Ceramide is synthesized via
sphingomylin (SM) recycling by sphingomylinases (SMase) at the inner and outer leaflets
of plasma membrane, lysosome, and perhaps other sphingomylin containing membranes
(such as of the mitochondria) and via a denovo synthesis pathway involving the ER (which
begins with condensation of L-serine, Ser, with palmitoyl-CoA, palmityl CoA, to produce
3-keto-sphinganine, 3KdhSph, which is reduced to dihydrosphingosine ,dhSph, and Nacylated to dihydroceramide, dhCer, which is desaturated to ceramide). Ceramide from
denovo synthesis is transported to the Golgi via CERT and between golgi compartments
via FAPP2. Golgi ceramide is modified to form SM and glucosylceramides (GluCer) used
to form other glycosphingolipids (GSL).
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GlcCer is transported between Golgi compartments by FAPP2141. Sphingomyelin,
which is localized to cell membranes throughout the cell, is an important structural lipid
and serves as a reservoir for ceramide for the synthesis of sphingosine and S1P. This
function is performed by neutral, acid, and alkaline sphingomyelinases142 and is rapidly
increased by chemotherapeutic agents, ultraviolet irradiation and other cell stresses143, 144.
To produce sphingosine, ceramidase removes the fatty acid chain from ceramide142. The
ATP dependent synthesis of S1P follows, accomplished by SphK1 and SphK2.
Ultimately, S1P is dephosphorylated back to sphingosine by S1P phosphatase isotype 1 or
2 which reside in the ER145, 146. S1P can also be degraded by an integral ER membrane
protein, S1P lyase, forming hexadecenal and phosphoethanolamine which is reused for the
biosynthesis of phosphatidylethanolamine147 .

SphK2
The most recently identified isotype of sphingosine kinase is SphK2. Although we
will be considering the role of a SphK1 specific inhibitor, SphK2 is of interest as it appears
to play both an opposing and complementary role to SphK1 in survival148. SphK2 is larger
and has a different amino terminus and central region than SphK1149.

Furthermore, it

possesses a BH3 like Bcl-2 family binding domain implicated in inducing apoptosis150.
SphK2b splice variant expression and nuclear translocation is increased in response to
serum deprivation and causes induction of apoptosis151. SphK2 is less substrate specific
than SphK1, phosphorylating substrates other than sphingosine including FTY-720,
converting this pharmacological agent into a S1P receptor agonist152-154. Lastly, SphK2
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overexpression and downregulation results in inhibition of cell growth and induction of
apoptosis155, 156 .

SphK1
In contrast to SphK2, SphK1 has been implicated in the pro-survival, proliferative
effects of S1P that were previously described. Owing to studies of basal SphK1 activity
and attenuation of growth response in SphK1 mutants unable to localize to the plasma
membrane, it seems likely that SphK1 effects are mediated by its membrane localization157,
158

. Phosphorylation on Ser225 by ERK2 is essential for this membrane affinity159. This is

consistent with the observation that sphingosine, SphK1's substrate, resides in the plasma
membrane. SphK1 is stimulated by a wide variety of plasma membrane receptor ligands,
particularly growth factors, including platelet-derived growth factor (PDGF)160, vascular
endothelial growth factor (VEGF)161, epidermal growth factor (EGF)162, and hepatocyte
growth factor163, as well as cytokines, tumor necrosis factor α164, hormones165, 166, GPCR
ligands, such as lysophosphtidic acid

167

and S1P168, as well as other ligands169. ERK1/2

phosphorylation by TNFα also appears to require SphK1 activity170. In addition, SphK1
directly interacts with TRAF2 (for TNF induced NF-κB activation protecting against
apoptosis)171, Calcium/calmodulin (which is important for SphK1 agonist induced
membrane translocation)172, platelet endothelial cell adhesion molecule 1173, delta
catenin174, aminoacylase175, SphK1 interacting protein176, and RPK118177.

Specific

knockdown of SphK1 by small interfering RNA triggers apoptosis in multiple tumor cell
lines178-182. Effector caspase and cytochrome c release was induced as well as significantly
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increased levels of ceramide and sphingosine in cells with suppressed SphK1
expression179. Thus SphK1 is implicated as a regulatory molecule in the signaling of a
number of different pro-survival signaling cascades and its knockdown often leads to
apoptotic cell death.

Sphingolipid metabolism and autophagy
Elements of the S1P metabolic pathway also have a role in inducing autophagy.
Increases in ceramide associated with tamoxifen treatment result in accumulation of
Beclin1, inhibition of Akt phosphorylation and autophagy. This effect is inhibited by
pharmacological inhibition of long chain ceramide production by fumonisin B1 and
replicated by short cell-permeant ceramide183. In addition, mTORC1 activity is inhibited,
however in contrast to nutrient starvation, Bcl-2 overexpression does not inhibit
autophagy183.
Interestingly, SphK1 overexpression is also capable of inducing autophagy. In this
case, while mTORC1 activity is inhibited, there is little change in beclin1 expression and
no decrease in Akt phosphorylation. Nor is the amount of endogenous ceramide shown to
change. These effects are inhibited by SphK1 RNA interference and the pan SphK
inhibitor N,N-dimethylsphingosine (DMS) which in turn increases cell death with PARP
cleavage.

In cells undergoing nutrient starvation, upregulation of SphK1 was also

observed88. It therefore appears that increases in ceramide result in autophagy associated
with cell death while SphK1 activation and increased S1P formation may serve to protect
cells.
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Pharmacological inhibitors of SphK1 have also been shown to induce autophagy.
Although not a SphK1 specific inhibitor, Safingol, a synthetic stereoisomer of sphinganine,
has been shown to inhibit PKC and SphK. Safingol treatment of the HCT116 colon
cancer cell line induces autophagy followed by cell death with concomitant decreases in
Akt phosphorylation, ERK phosphorylation and mTORC1 activity.

Safingol did not

however induce increases in ceramide, S1P or dihydroceramide and autophagy induced by
PKC depletion with siRNA was not of comparable intensity to that induced by Safingol 89.
Thus, the activity of S1P appears central to cell survival and its biosynthetic pathways
overlap cell structures sensitive to autophagic induction.

SK1-I
SK1-I is a water soluble sphingosine analogue shown to competitively inhibit S1P
production by SphK1 without inhibiting the catalytic activities of SphK2, PKC or a
number of other protein kinases (Fig 4). SK1-I decreases growth and survival in human
leukemia U937 and Jurkat cells and caspase inhibitors and overexpression of Bcl-2 protect
against apoptosis induced by SK1-I184 .
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Safingol
Fig4: Structure of SK1-I 184
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Statement of Intent
Autophagy is the process of “cell self-eating” thought to provide essential nutrients
to the cell under conditions of nutrient restriction. Recent observations, however, suggest
that significantly elevated rates of autophagy induce apoptosis-independent cell death.
Sphingosine Kinase 1 (SphK1) catalyzes the synthesis of sphingosine 1 phosphate, a
bioactive lipid signaling molecule which has been shown to suppress apoptosis and
stimulate cell growth, proliferation and motility. Moreover, it has been shown that SphK1
induced autophagy protects cells from apoptosis during nutrient starvation88. This study
seeks to determine whether Sphingosine Kinase 1 Inhibitor (SK1-I), a specific inhibitor of
SphK1, regulates autophagy, to identify the mechanism of its action, and to evaluate the
impact of SK1-I induced autophagy on HCT116 colon cancer cell viability.
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Materials and Methods

Materials
SK1-I,

(2R,3S,4E)-N-methyl-5-(4'-pentylphenyl)-2-aminopent-4-ene-1,3-diol

(BML-258), was synthesized as the HCl salt by BIOMOL International (Plymouth
Meeting, PA).

Propidium iodide for membrane integrity analysis and bisbenzimide

Hoechst 33342 for nuclear staining were obtained from Sigma Aldrich (St. Louis, MO).
LY94002 was obtained from Biomol (Plymouth Meeting, PA).

Cells
Wild type and p53 null HCT116 human colorectal carcinoma cells were obtained
from American Type Culture Collection (Manassas, Va).

Cells were cultured and

maintained in logarithmic growth phase in Dulbecco's Modified Eagle Medium 11995
containing 4,500 mg/L D-glucose, L-glutamine, and phenol red (DMEM, Invitrogen,
Carlsbad CA) supplemented with 10% fetal calf serum (Invitrogen, Carlsbad CA). During
SK1-I treatment, cells were cultured in DMEM supplemented with 0.1% fatty acid free
BSA (Sigma Aldrich, St. Louis, MO).

Cell Transfection
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Cells were plated on poly-L-lysine covered glass coverslips in a 6 well plate at 1
million cells per well. After 24 hours, cells were transfected using Lipofectamine 2000
according to the manufacturer's protocol (Invitrogen, Carlsbad CA). Cells were transfected
with pEGFP-C1-rLC3 plasmid (kindly given by T. Yoshimori, National Institute of
Genetics, Mishima, Japan). 24 hours after transfection, cells were cultured in DMEM
containing 0.1% BSA and treated with SK1-I as indicated in figure legends.

RNA interference
Cells were plated on poly-L-lysine covered glass coverslips in a 6 well plate at
300,000 cells per well.

After 24 hours, cells were transfected using Oligofectamine

according to the manufacturer's protocol (Invitrogen, Carlsbad CA) with either 100 nM
Smartpool siRNA for Atg5 (Thermo Scientific Dharmacon, Lafayette, CO) or 100nM
siRNA for Beclin 1 (Qiagen, Valencia, CA). Cells were transfected with pEGFP-C1-rLC3
24 hours after siRNA transfection using Lipofectamine 2000. 24 hours later, cells were
then cultured in DMEM containing 0.1% BSA and treated with SK1-I as indicated in
figure legends.

Confocal Microscopy
Cells grown on glass cover slips were fixed using 3.7% paraformaldehyde (Sigma
Aldrich, St. Louis, MO) in phosphate buffered saline. Cover slips were mounted using 10
nM N-propyl gallate (Sigma Aldrich, St. Louis, MO). Images were acquired with a Zeiss
LSM 510 confocal microscope with a 63x objective lens. Excitation (ex.) and emission
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(em.) filter settings were: GFP ex. 488 nm, em. long pass 505. The number of GFP-LC3
positive cells with more than 5 GFP-LC3 dots was determined. Quantification was
performed by Dr. Sandrine Lépine.

Western blot analysis
Adherent and detached cells were collected and resuspended in cell lysis buffer (20
mM Tris (pH 7.5), 150 mM NaCl, 1mM EDTA, 2.5 mM sodium pyrophosphate, 1mM βglycerophosphate, 1 mM sodium orthovanadate, 1%Triton X-100, Sigma protease inhibitor
cocktail). Lysates were sonicated and centrifuged. After protein quantification (Bio-Rad,
Hercules, CA), equal amounts of protein were separated by 10% sodium dodecyl sulfide–
polyacrylamide gel electrophoresis (SDS-PAGE) and then transblotted to nitrocellulose.
Blots were incubated with primary antibodies overnight in Tris-buffered saline (TBS)
containing 3%BSA.
The following were used as primary antibodies at 1:1000 dilution (except in the
case of Phospho-Akt, 1:500): Phospho-Akt(Ser473) (rabbit polyclonal), Akt (rabbit
polyclonal), Phospho-mTOR(Ser2448)(rabbit polyclonal), mTOR (rabbit polyclonal),
Phospho-Erk1/2 (Thr202/Tyr204) (rabbit polyclonal), Erk2(rabbit polyclonal), PhosphoeIF2α (Ser 51) (rabbit polyclonal), Clathrin Heavy Chain (rabbit polyclonal) (Cell
Signaling, Beverly, MA), Beclin (mouse polyclonal) (BD Pharmingen, San Diego, CA),
and anti-PARP (rabbit polyclonal) (BIOMOL International), APG5L (rabbit polyclonal)
(Abgent, San Diego, California), LC3 (rabbit polyclonal) (Novus Biologicals, Littleton,
CO).
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After washing, cells were incubated for one hour at room temperature with
peroxidase conjugated anti–rabbit or anti-mouse IgG (1:10 000; Jackson Immunoresearch
Laboratories, West Grove, PA). Immunocomplexes were visualized using Super Signal
West substrate (Thermo Fisher Scientific, Rockford, Illinois) with Kodak (Rochester, NY)
or Phenix Research Products (Candler, NC) X-ray film.

Cell Death Assay
Cells were plated at four hundred thousand cells per well in a 6 well plate. Cells
were given 24 hours to adhere. Cells were then cultured in DMEM containing 0.1% BSA
in the absence or presence of 10 μM SK1-I for 24 hours. Apoptotic and necrotic cells were
quantified by fluorescence microscopy after labeling with Hoescht 33342 (10 µg/ml) and
propidium iodide (50µg/ml). Cells were visualized with a Nikon eclipse TE300
fluorescence microscope. Cells exhibiting blue condensed or fragmented nuclei or red
condensed nuclei were considered apoptotic. Red nuclei without signs of condensation or
fragmentation were considered necrotic.

Statistical Analysis
For each experiment, data from samples were calculated and expressed as the mean
plus or minus standard deviation (SD). The significance of differences between
experimental conditions was determined using the Student t test for unpaired observations.
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Results
SK1-I Induces autophagy in a time and dose dependent manner
Previous studies have shown that upregulation of SphK1 expression associated with
increases in S1P result in increased autophagic vesicle formation88. As such, it was of
interest to investigate the effect on autophagy of the isotype specific sphingosine kinase 1
inhibitor, SK1-I184 .
In this study we used HCT116 wild type p53 and p53 null cells as our model
system. First we verified that p53 null cells did not express p53. This was demonstrated
by western blot (Fig 5A) of p53.
In order to visualize autophagosome accumulation, we observed changes in
localization and lipidation of LC3, a protein whose attachment to the isolation membrane
(unenclosed autophagosomal precursor) is considered necessary for autophagosome
formation51. Shortly after translation, LC3’s carboxy terminal region is cleaved creating
LC3I. Upon induction of autophagy, LC3I is lipidated with phosphatidylethanolamine
forming LC3II. LC3II specifically localizes to the developing autophagosome membrane
51,185

. GFP-LC3 also undergoes this process thereby labeling autophagosomal structures

with GFP in a manner consistent with direct immunohistochemical staining185. Thus, in
order to determine whether SK1-I induces autophagosome formation, we transfected
HCT116 colon cancer cells with a plasmid expressing GFP conjugated LC3 and autophagy
was quantified using confocal microscopy. In vehicle treated cells in which no autophagy
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was induced, GFP staining appeared as a diffuse light green fluorescence present in the
cytosol. In cells with autophagy, GFP fluorescence appeared as concentrated green puncta.
One limitation of this method is that GFP-LC3 is prone to form aggregates which resemble
GFP-LC3II puncta186. Furthermore, cells are expected to engage in some basal level of
autophagy. Therefore, we quantified the number of cells with more than GFP-LC3 puncta
in a double blind manner. We observed that SK1-I induced an elevated level of autophagic
vesicle formation in a time and dose dependent manner (Fig. 5). Because p53 has been
shown to be involved in autophagy187, we examined whether the effect of SK1-I on
autophagy was influenced by the presence of p53 expression. Both wild-type and p53 null
HCT116 cells had significant levels of autophagy within 3 hours of exposure to 10μM
SK1-I (Fig 5b). 35 percent of cells expressing wild type p53 and 32 percent of p53 null
cells were autophagic. Wild type cells continued to become increasingly autophagic until
approximately 24 hours at which time 67 percent were autophagic and rates leveled off.
p53 null cells became increasingly autophagic until 12 hours at which time approximately
40 percent of cells exhibited maximal autophagy (Fig. 5b). Similarly, significant increases
in response to SK1-I concentration were observed in both wild type and p53 null cells
when cultured in 10μM SK1-I for 6 hours as compared to cells cultured at 3 or 5μM SK1-I
(Fig 5c). At 10μM SK1-I, 41 percent of wt cells and 23 percent of p53 null cells were
autophagic. Thus there was a significantly higher percentage of punctate staining in wild
type cells than in p53 null cells in response to SK1-I treatment (Fig. 5).
SK1-I induction of autophagy was confirmed using western blot (Fig 6). As a
result of its lipidation, LC3II has greater mobility than LC3I in SDS-PAGE185. Increases
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in LC3 lipidation and thus accumulation of autophagosomes can therefore be evaluated
based on the differential induction of LC3I and LC3II in response to treatment. LC3
lipidation increased as a function of SK1-I time and dose as seen by an increase in LC3II
intensity relative to LC3I (Fig. 6). Interestingly, in SK1-I treated cells, earliest increases in
lipidation were observed at 15 minutes (Fig. 6a). The lowest concentration at which SK1-I
elicited a response appeared to be 10μM (Fig. 6b). As such, 10μM SK1-I was used for all
other experiments.

SK1-I does not trigger classical Beclin 1 or mTORC1 signaling
Increases in Beclin1 protein have commonly been associated with autophagy
induction27, 42, 183. We therefore examined changes in Beclin1 protein expression during
the three hour period in which autophagy was seen to be initiated. Western blot of whole
cell lysates showed that Beclin 1 protein levels were not upregulated in HCT116 wt or
p53-/- cells after exposure to SK1-I (Fig. 7 A, B). Previous studies have also shown that in
cases in which Beclin1 protein levels do not change, interactions with other protein factors
mediate autophagic induction in a Beclin1 dependent fashion (UVRAG65, Ambra66,
Bcl-267). To eliminate this possibility, Beclin1 protein expression was downregulated
using short interfering RNA for Beclin1. The efficiency of Beclin 1 downregulation was
confirmed by western blotting for Beclin1 protein (Fig 8). Examination of LC3 lipidation
by western blot revealed that downregulation of Beclin 1 did not attenuate induction of
autophagy with SK1-I (Fig. 8). Beclin1 and its interactions with other regulatory proteins
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(i.e. UVRAG, Ambra, or Bcl-2) was therefore considered unlikely to mediate autophagy
induction by SK1-I.
Next, the role of rapamycin sensitive mTOR complex (mTORC1) was considered.
mTORC1 integrates numerous growth factor and nutrient signaling pathways and regulates
the transcriptional response to these pathways188.

Most commonly, mTORC1 is

considered to be downstream of Akt and ERK 75, 76, 189 although the exact mechanism of its
activation is unclear. In mammalian cells, inhibition of mTORC1 is sufficient to induce
autophagy and is required for autophagy due to nutrient starvation84-86 .
Changes in mTORC1 activity were evaluated by blotting for PhosphomTOR(Ser2448).

During the first three hours of SK1-I treatment (when there is a

significant increase in autophagy), mTOR phosphorylation was not seen to be reduced
relative to control (Fig. 9). We therefore conclude that there is no significant change in
mTORC1 activity in response to SK1-I treatment.

Non-canonical mTORC2 signaling is observed
The downstream signaling of the rapamycin insensitive mTOR complex
(mTORC2) was then examined. mTORC2 downregulation was shown to induce FoxO3
nuclear translocation in transfected myofibers, which correlated with expression of
autophagy inducer BNIP protein. A resulting increase in autophagosome formation was
observed independent of mTORC1 inhibition99.
mTORC2 has been identified as the primary complex to phosphorylate Akt on
Ser47395. Phosphorylation of Akt ser473 was evaluated by western blot as a downstream
45

target of mTORC2 activity. It was observed that phosphorylation of Akt at Serine 473 was
consistently lower in SK1-I treated cells than in vehicle treated cells (Fig. 10a).
Furthermore, induction of LC3 lipidation was observed at the same time point as this
decrease in Akt phosphorylation (Fig. 10b).

Akt is not involved in autophagy
In order to investigate the effects of potential Akt inhibition on autophagy
induction, cells were treated with LY294002 a specific inhibitor of type1 PI3kinase
inhibit Akt phosphorylation.

190

to

Akt (Ser 473) and downstream target mTOR(Ser2448)

phosphorylation were examined. LY294002 resulted in more intense reductions in Akt
and mTOR phosphorylation than did SK1-I (Fig. 11). Even so, autophagic response to
SK1-I treatment was observed to be much stronger than that induced by inhibition of Akt
phosphorylation and mTORC1 inactivation (Fig. 11). An additive effect by LY294002
and SK1-I treatment on LC3 lipidation was observed. Taken together, this data suggests
that inhibition of phosphorylation of Akt may not be a major contributor to SK1-I induced
autophagy.

SK1-I induced ER stress
ER stress and the unfolded protein response (UPR) have been implicated in
autophagy109. Furthermore, the UPR does not require Beclin1 for activation191. During
ER stress, protein kinase r-like ER kinase (PERK) is activated in response to decreases in
calcium or protein misfolding. In turn it phosphorylates transcription factor eIF2alpha107,
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192

. eIF2alpha phosphorylation is also necessary for Atg 12 mediated LC3 conversion

during autophagy due to aggregation of polyglutamine repeat proteins in the ER102.
EIF2alpha phosphorylation was examined by Western blot.

eIF2alpha showed

significantly elevated levels of phosphorylation in comparison with untreated cells
beginning within 15 minutes of treatment with SK1-I (Fig. 12), similar to the time course
observed in LC3 lipidation (Fig 2a). In addition, eIF2alpha phosphorylation was seen to
increase in response to 6 hours treatment with 10μM SK1-I rather than 5μM SK1-I, just as
was observed for LC3II appearance (Fig. 6b). These results indicate that SK1-I induces
ER stress that could be responsible for SK1-I induced autophagy.

Atg5 is necessary for SK1-I autophagic induction
To determine whether other elements of the canonical autophagy induction
pathway were necessary for accumulation of LC3 associated vesicles in SK1-I treated
cells, small interfering RNA for Atg5 was used. Atg5 has been shown to localize to the
isolation membrane and be necessary for autophagosome formation25. Small interfering
RNA for Atg5 inhibited induction of autophagy as measured by LC3 lipidation (Fig. 8).
This confirmed that LC3 lipidation was dependent upon Atg5, a known participant in
autophagic vesicle nucleation.

SK1-I induces non-apoptotic cell death in wild type HCT116 cells and apoptosis in
p53 null cells
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Cell survival in response to SK1-I was then examined. Propidium Iodide staining
in combination with Hoechst 33342 has been shown an effective method of visualizing
membrane permeablization, and nuclear condensation, respectively193.
condensation is considered a cytological marker of apoptosis193.

Nuclear
Membrane

permeablization without nuclear condensation is considered to indicate non-apoptotic cell
death193. By propidium iodide staining, 94 percent of wild type cells cultured in 10μM
SK1-I for 24 hours were observed to be membrane permeablized without nuclear
condensation (Fig. 13). P53 null HCT116 cells treated with SK1-I were observed to have a
higher percentage of apoptosis (35 percent) than control (3 percent) or wild type cells (3
percent), with insignificant amounts of membrane permeablization (Fig. 13). While p53
null cells underwent apoptosis, wild type cells appeared highly susceptible to a nonapoptotic form of cell death.
To confirm the observation of non-apoptotic cell death in wild type HCT116 cells,
Poly-(ADP-ribose) polymerase (PARP) cleavage was evaluated by western blot. PARP is
a nuclear protein implicated in DNA repair. PARP is one of the earliest proteins targeted
for specific caspase cleavage and the best characterized caspase substrate in measuring
apoptotic cell death194. No PARP cleavage was detected in wild type HCT116 cells up to
24 hours (Fig. 14) indicating that the permeablization observed in these cells is not a result
of apoptotic cell death. ERK phosphorylation was also observed as an indicator of cell
survival. ERK phosphorylation was reduced in both wild type and p53 null cells (Fig. 15),
suggesting that this does not contribute to the distinct apoptotic responses of p53 null
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HCT116. Altogether these results demonstrate that SK1-I induced a non-apoptotic cell
death in HCT116 wt cells while inducing apoptosis in HCT116 p53 null cells.
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Figure 5. SK1-I Induces autophagy with different intensity in human wild type p53
expressing HCT116 colon carcinoma cells, and in their p53-null counterparts.
A. Equal amounts of lysate proteins from naive wild type and p53 null HCT116 cells were resolved
by SDS-PAGE and analyzed by western blotting with antibodies against p53. Blots were stripped
and reprobed for βTubulin to demonstrate equal loading and transfer. B-D. LC3-GFP transfected
wild type and p53null HCT116 cells cultured in DMEM supplemented with 0.1%BSA were treated
with 10μM SK1-I in for the indicated time (B,C) or with the indicated concentrations of SK1-I for
6 hours (D). Cells were examined by confocal fluorescence microscopy. (B) Representative images
are shown. Scale bars, 10 µm. (B) Percentage of cells showing GFP-LC3 fluorescence in puncta
was quantified. Data are means ± SD.
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Figure 6: SK1-I induces LC3 lipidation in HCT116 cells.
A,B. Naive HCT116 cells cultured in DMEM supplemented with 0.1%BSA were treated
without or with 10μM SK1-I for the indicated times (A) or with the indicated
concentrations of SK1-I for 6 or 24 hours (B). HCT116 cells were also cultured with
2%FCS for 6 hours and 24 hours as a control. Equal amounts of lysate proteins were
resolved by SDS-PAGE and analyzed by western blotting with antibodies against LC3.
Blots were stripped and reprobed for total Akt, Clathrin Heavy Chain, or βTubulin to
demonstrate equal loading.
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Figure 7: SK1-I induces autophagy without increasing Beclin1.
Wild type (A) and p53 null (B) HCT116 cells cultured in DMEM supplemented with
0.1%BSA were treated without or with 10μM SK1-I for the indicated times. Equal
amounts of lysate proteins were resolved by SDS-PAGE and analyzed by western blotting
with antibodies against Beclin1. Blots were stripped and reprobed for βTubulin to
demonstrate equal loading.
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HCT116 wt cells were transfected with siControl, siBeclin or siATG5 then transfected
with LC3-GFP. Cells were cultured for 24 hours then treated with without or with the
indicated concentrations of SK1-I in DMEM supplemented with 0.1%BSA for 6 hours.
Equal amounts of lysate proteins were resolved by SDS-PAGE and analyzed by western
blotting with antibodies against LC3. Blots were stripped and reprobed for Beclin1 to
ensure protein expression knockdown. Blots were stripped and reprobed for Clathrin
Heavy Chain to demonstrate equal loading.
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Figure 9: SK1-I does not inactivate mTOR complex 1.
Wild type and p53 null HCT116 cells cultured in DMEM supplemented with 0.1%BSA
were treated without or with 10μM SK1-I for the indicated times. Equal amounts of lysate
proteins were resolved by SDS-PAGE and analyzed by western blotting with antibodies
against Phospho-mTOR(Ser2448). Blots were stripped and reprobed for mTOR for
comparison with phosphorylation. Blots were stripped and reprobed for Erk2 to
demonstrate equal loading.
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Figure 10: SK1-I treatment decreased phosphorylation of Akt concomitantly with
LC3 lipidation.
Wild type and p53 null HCT116 cells were treated without (-) or with 10μM SK1-I (+) for
the indicated times. Equal amounts of lysate proteins were resolved by SDS-PAGE and
analyzed by western blotting with antibodies against Phospho-Akt (Ser473) (A and B).
Blots were stripped and reprobed for Erk2 (A) or total Akt (B) to demonstrate equal
loading.
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Figure 11: SK1-I induces autophagy independently of Akt and mTORC1
CT116 cells cultured in DMEM supplemented with 0.1%BSA were treated with 10μM
LY294002 or 10μM SK1-I or a combination of both for 30 minutes. Equal amounts of
lysate proteins were resolved by SDS-PAGE and analyzed by western blotting with
antibodies against Phospho-mTOR(Ser2448), LC3 and Phospho-Akt. Blot was stripped
and reprobed for Clathrin Heavy Chain to demonstrate equal loading.
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Figure 12: SK1-I treatment induces ER stress
Wild type and p53 null HCT116 cells cultured in DMEM containing 0.1% BSA were
treated without (-) or with 10μM SK1-I (+) for the indicated times (A) or with the indicated
concentration of SK1-I for 6 hours and 24 hours (B). Equal amounts of lysate proteins
were resolved by SDS-PAGE and analyzed by western blotting with antibodies against
Phospho-eIF2α (A) or Phospho-eIF2α and LC3 (B). Blots were stripped and reprobed for
Erk2 (A) or βTubulin (B) to demonstrate equal loading.
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C.

untreated HCT116 wt (Hoechst Blue, PI red)

SK1-I HCT116 wt (Hoechst Blue, PI red)

Figure 13: SK1-I induces non-autophagic death in wild type HCT116 cells and
apoptosis in p53-/- HCT116 cells.
Wild type and p53 null HCT116 cells were treated with 10μM SK1-I for 24 hours. Cells
were fixed and stained with propidium iodide and Hoechst and percentage of cells with
permeablized membranes (A) or condensed nuclei (B), respectively, were counted. C.
representative field of untreated wild type HCT116 cells (top) or 10μM SK1-I treated for
24 hours (bottom).
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Figure 14: SK1-I did not induce PARP cleavage in wt cells.
HCT116 cells were treated without (-) or with 10μM SK1-I (+) for the indicated times.
Equal amounts of lysate proteins were resolved by SDS-PAGE and analyzed by western
blotting with antibodies against PARP. Blots were stripped and reprobed for Clathrin
Heavy Chain to demonstrate equal loading.

60

HCT116 p53 null
Minute
SK1-I

0
-

5
- +

15
- +

30
- +

60
- +

HCT116 wt
120
- +

180
- +

0
-

5
- +

15
- +

30
- +

60
- +

120
- +

180
- +

p- ERK
ERK2

Figure 15: SK1-I decreases ERK1/2 phosphorylation
Wild type and p53 null HCT116 cells were treated without (-) or with 10μM SK1-I (+) for
the indicated times. Equal amounts of lysate proteins were resolved by SDS-PAGE and
analyzed by western blotting with antibodies against Phospho-Erk1/2. Blots were stripped
and reprobed for Erk2 to demonstrate equal loading.
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Discussion

Autophagy Induction by SK1-I: an Unexpected Result
Autophagy has traditionally been associated with the adaptive responses of nutrient
deprived cells. This nutrient response was primarily associated with increased Beclin 1
activity and decreased mTORC1 activity84-86. Recently, however, autophagy has been
associated with maintaining cell homeostasis and in some cases contributing to cell
death22. This study places the effects of the isotype SphK1 inhibitor SK1-I within this new
paradigm and investigates its mechanism of action. In many respects, the findings of this
study differ significantly from the previously reported observations of autophagy induced
by SphK1 upregulation

88

and ceramide increase183, suggesting a novel mechanism of

autophagy induction.
SK1-I treatment increased autophagy significantly in cells expressing or lacking
p53. This increase in autophagy was unusual in three aspects. Firstly, very rapid induction
of autophagy was observed.

By western blotting to examine LC3 lipidation, it was

possible to observe LC3 conversion in response to SK1-I treatment within 15 minutes.
This finding was difficult to compare with previous investigations of autophagy as they
often only evaluated autophagy after longer periods of time. Nevertheless, Tasdemir et al.
2008195 , showed that in HCT116 cells wild type for p53, lithium (IP3R antagonist),
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tunicamycin, rapamycin or ABT737 (Bcl-2 inhibitor, BH3 mimetic small molecule)
typically required more than 1 hour to demonstrate changes in LC3 lipidation195. In other
experiments, ligand induced JNK activation

196

or IP3R antagonism
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was observed to

require 12 hours of treatment for autophagy induction. Other studies evaluating
sphingolipid metabolites such as that investigating 100 µM C2-Cer induced autophagy and
nutrient starvation, only evaluate autophagy after 4 hours of treatment69.
Secondly, autophagy was induced more profoundly in cells expressing wild type
p53 than in cells which p53 was absent. Tasdemir et al 195 have proposed that cytoplasmic
p53 is degraded during the autophagic process. In HCT116 cells, it was observed that
cytosolic p53 inhibition, depletion or deletion causes a maximal level of autophagy that
cannot be enhanced by chemical agents used to trigger nutrient deprivation or ER stress 195.
Furthermore, induction of autophagy by these agents can be inhibited by preventing the
degradation of p53. This inductive effect is, however, cell cycle dependent and only
causes autophagy in G1or S phase.

In contrast, nuclear p53 is known to promote

transcription of pro-autophagy factors such as the DAPK proteins197.

It is difficult,

therefore to implicate p53 directly in this differential induction of autophagy except
perhaps as regulator of the cell cycle, allowing cells to spend more time in highly
autophagic G1 or S phase, and as potential transcription factor. It was, however, noted (as
seen in differential phosphorylation levels of eIF2α, mTOR, Akt and ERK proteins and
unreported blotting of EGF receptor phosphorylation), that wild type p53 and p53 null
cells displayed significant differences in the basal status of signaling pathways normally
associated with autophagy.

These differences, which may or may not be directly
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associated with p53 status, may also account for some difference in autophagy intensity
induced by SK1-I.
Lastly, inhibition of SphK1 using RNA interference or DMS in MCF7 breast
cancer cells was previously reported to attenuate the autophagic response induced by
nutrient starvation or SphK1 upregulation88.

Our observation of a rapid increase in

autophagy using SK1-I is quite distinct from this earlier report. However, observations by
Coward et al (2009) that safingol, an unspecific SphK and PKC inhibitor, induces
autophagy more strongly than can be accounted for by PKC inhibition alone, and without
concomitant increases in sphingosine, S1P, or ceramide metabolites89, lead one to wonder
what effects SK1-I has on sphingolipid metabolite levels at early time points and whether
its accumulation or modification may account for its effects (it could, for example, it be Nacylated to become a dihydroceramide analogue as does safingol 198 and induce autophagy
through a similar mechanism as resveratrol which shares beclin1 independent
characteristics.

In addition, the anti ceramide-tunnel forming characteristics of

dihydroceramide would help to account for the lack of apoptosis in wild type cells199).
Interestingly, SK1-I also induced rapid autophagy in glioblastoma cells (D. Kapitonov,
unpublished) and SK1-I treatment induced a very rapid decrease in S1P (within 20
minutes). This was followed by an increase in sphingosine at 1 hour and a later increase in
ceramide (D. Kapitonov et al, submitted to Cancer Research). Therefore, the potent effect
on autophagy of SK1-I could be due to a lack of intracellular S1P or increases in
sphingosine and ceramide. In order to investigate this possibility in HCT116 cells, massspectophotometric analysis of cells treated with SK1-I at early time points should be
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performed examining SK1-I and sphingolipid metabolites. In turn, detected differences in
quantity and structure of these metabolites should be introduced as alternative treatment
conditions and compared with the SK1-I effect.

Absence of Beclin1 or mTORC1 effects offer mechanistic insights
Although Beclin 1 is considered to have a significant role in regulating autophagy,
no such involvement was observed with SK1-I. Previously, genetic upregulation of Beclin
levels have been shown to induce autophagy27. Futhermore, in response to ceramide, a
robust increase in Beclin1 has been observed183.

Even without changes in Beclin

expression, starvation induced autophagy is inhibited by Bcl-2 binding to Beclin
Bcl-2 binding is regulated by its ceramide dependent phosphorylation69.
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and

Ambra and

UVRAG also regulate autophagy by mediating the interaction between Beclin 1 and
Vps3465,
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. The observed down regulation of total Beclin1 expression in this study,

without significant inhibition of autophagy, however, suggests that these Beclin 1
regulatory mechanisms do not have a significant role in the SK1-I induced autophagic
effect. While not conclusive, these results also cast doubt on the possibility that ceramide
may be the primary cause of SK1-I induced autophagy. This further emphasizes the need
for investigation of SK1-I induced changes in sphingolipid metabolism during early SK1-I
treatment. Furthermore, it may be of interest to compare the effects of Resveratrol, which
induces a Beclin 1 independent, dihydroceramide mediated, form of autophagy70,135, with
those of SK1-I.
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Inhibition of mTORC1 is also commonly observed with induction of autophagy,
and yet was not observed in SK1-I treated cells.

In mammalian cells, inhibition of

mTORC1 is sufficient to induce autophagy and is required for autophagy due to nutrient
starvation84-86. Elevated mTORC1 activity results in cells with impaired ability to initiate
autophagy in response to nutrient starvation85.

Reduced mTORC1 activity has been

observed in autophagic cells as a result of ER stress associated with Ca activated AMPK
signaling68, elevated SphK1 expression88, elevated ceramide levels69, and treatment with
Safingol89. Our results are consistent with the notion that autophagy is not being induced
by a nutrient starvation pathway. We also observed that Akt activity and downstream
signaling through mTORC1 does not account for autophagy induced by SK1-I. Complete
downregulation

of

Akt

phosphorylation

and

downstream

decrease

in

mTOR

phosphorylation resulted in little increase in LC3 lipidation while SK1-I treatment, with
comparatively much less inhibition of Akt and mTOR phosphorylation , resulted in a much
higher rate of LC3 lipidation. Furthermore, treatment with both the Akt inhibitor and SK1I appeared to produce an additive effect on LC3 lipidation. Owing to Akt's importance in
S1P receptor signaling, this may support the possibility of an intracellular mechanism of
action.
Interestingly, changes in mTORC1 activity have not been observed in autophagy
induced by PKCθ in response to calcium90, or IP3R in response to reduction in IP3R
expression91.

Therefore, further investigation of these ER associated mechanisms of

autophagy may provide some insight into the mechanism of SK1-I induced autophagy.
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Translational effects, cytoskeletal changes, and a role for the ER
Ultimately, inhibition of autophagy by knockdown of Atg5 confirmed that SK1-I
effects were dependent upon the conserved mechanism of initial autophagosome
formation. Therefore, investigation of other, less conventional autophagic pathways
seemed warranted. The observation that Akt serine 473 dephosphorylation and eIF2α
phosphorylation occur concomitantly with the first observed increase in LC3 lipidation
suggest a role for mTORC2 and ER stress in mediating autophagy induced by SK1-I.
mTORC2 is of particular interest in SK1-I induced autophagy because it is
considered to play a role in regulation of the actin cytoskeleton
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much as has SphK1200.

In addition, growth factor independent mTORC2 activity has been shown to be necessary
for carboxyl-terminal folding and stabilization of newly synthesized Akt and PKC96.
mTORC2 downregulation has been shown to induce FoxO3 nuclear translocation in
transfected myofibers, which correlates with expression of autophagy inducer BNIP
protein. Autophagosome formation is observed in response to mTORC2 inhibition without
mTORC199. Changes in cytoskeletal organization, inhibition of protein synthesis and
autophagic protein expression could all contribute to an autophagic effect. Therefore,
further investigation of co-localization, constituitive activation and downregulation of
mTORC2's binding constituents in relation to SphK1 may shed light on a new intracellular
mechanism of SphK1 action.
In response to perturbations in protein folding/glycosylation, shuttling of proteins
to the Golgi, ER calcium balance, and synthesis of fatty acids, sterols and phospholipids,
ER stress is induced19. Each of these perturbations may also induce autophagy109. There is
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some evidence that calcium release from the ER is the primary signal initiating the ER
mediated autophagic response109.

ER stress results in eIF2α phosphorylation192.

Furthermore, eIF2α phosphorylation has been shown necessary for LC3 conversion by
induction of Atg12 during ER stress caused by aggregation of polyglutamine repeat
proteins102.

Based on the finding that eIF2α is phosphorylated in response to SK1-I

treatment, ER stress due to protein misfolding and modification,

ER integrity, lipid

synthesis and trafficking, and calcium homeostasis should be further investigated as
mediators of SK1-I autophagy. Furthermore, treatment of HCT116 cells with non-specific
SphK inhibitor N,N-dimethyl-D-erythro-sphingosine (DMS) a sphingosine analogue, has
been shown to induce cytosolic calcium release by an IP3R independent mechanism201.
As such, one first step in this process is to confirm that cytosolic calcium chelation cannot
inhibit autophagy and that signaling through a known ER stress sensor is necessary for
SK1-I induced autophagy as would be demonstrated by sensor knockdown102,
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.

Furthermore, because the mitochondria are in such close apposition to the ER, and the ER
plays a role in mitochondrial homeostasis, mitochondrial changes may also be considered.

Autophagic Death? Need for Further Investigation of the Mechanisms of Death
Lastly, SK1-I causes non-apoptotic and apoptotic death including reductions in Akt
and ERK phosphorylation. In addition, death was induced differentially in wt and p53 null
cells. This may be accounted for by the intensity of autophagy induction in each cell type
and other observed differences between wt and p53 null cells. However, to determine the
relationship between autophagy, apoptosis, and cell death, inhibition of autophagy using
68

siAtg5 and observations of the resulting cell viability and death signaling may be
worthwhile.
In sum, SK1-I rapidly induces autophagy with non-canonical signaling involving
decreased mTORC2 activity and ER stress. The result is cell death whose differential
expression in wild type p53 and p53 null cell lines parallels their differences in autophagic
intensity. The relationship of these observations to sphingolipid metabolism and putative
changes in ER homeostasis or mTORC2 activity warrants further investigation as does the
clinical utility of SK1-I in the treatment of cancer or other conditions in which cytotoxicity
or autophagy may have therapeutic value.
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